Eli Lilly and Co (LLY) Position Boosted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC boosted its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 11.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 372,594 shares of the company’s stock after acquiring an additional 38,354 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Eli Lilly and were worth $31,467,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Accredited Investors Inc. boosted its holdings in Eli Lilly and by 0.4% during the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after acquiring an additional 14 shares during the period. Oakworth Capital Inc. boosted its holdings in Eli Lilly and by 0.3% during the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after acquiring an additional 20 shares during the period. Sfmg LLC boosted its holdings in Eli Lilly and by 0.5% during the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after acquiring an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. boosted its holdings in Eli Lilly and by 0.7% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock valued at $300,000 after acquiring an additional 24 shares during the period. Finally, YorkBridge Wealth Partners LLC boosted its holdings in Eli Lilly and by 0.8% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock valued at $265,000 after acquiring an additional 24 shares during the period. Institutional investors own 76.31% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold a total of 251,088 shares of company stock valued at $22,041,236 over the last 90 days. 0.20% of the stock is currently owned by company insiders.

A number of equities analysts recently issued reports on the company. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 5th. Leerink Swann upped their target price on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a report on Wednesday, December 13th. Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Finally, Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and upped their target price for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $92.14.

Shares of Eli Lilly and Co (NYSE:LLY) traded up $0.60 during midday trading on Friday, hitting $86.99. The company had a trading volume of 2,106,496 shares, compared to its average volume of 3,260,000. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The stock has a market cap of $95,770.00, a PE ratio of 41.42, a P/E/G ratio of 1.62 and a beta of 0.35. Eli Lilly and Co has a 1 year low of $74.00 and a 1 year high of $89.09.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The firm had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 EPS. analysts predict that Eli Lilly and Co will post 4.22 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is 99.05%.

ILLEGAL ACTIVITY WARNING: This report was first reported by BBNS and is the sole property of of BBNS. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://baseballnewssource.com/markets/eli-lilly-and-co-lly-position-boosted-by-nisa-investment-advisors-llc/1826828.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with our FREE daily email newsletter.

 


Latest News

Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Rumor: Braves Show Interest in Reamluto, Yelich
Rumor: Braves Show Interest in Reamluto, Yelich


Leave a Reply

 
© 2006-2018 BBNS.